July 2, 2026

Written by Dr. Vincent Angelico

ENDS stands for electronic nicotine delivery systems, the category that includes vapes, e-cigarettes, disposables, and pod systems. For an ENDS application, the switching-study question used to have a fairly standard answer. After the FDA’s GLAS authorization in May 2026, the answer now turns on three things: the type of device, the flavor, and whether the device has effective onboard age-gating. Onboard age-gating means built-in technology that verifies the user is an adult and keeps the device from working for anyone else. The FDA also calls this device access restriction, or DAR. 

A premarket tobacco product application, or PMTA, is the application a company files to get FDA permission to sell a nicotine product. 

The governing law has not changed. Under Section 910 of the Federal Food, Drug, and Cosmetic Act and 21 CFR Part 1114, an application must support a finding that marketing the product is appropriate for protecting public health, often shortened to APPH. FDA judges this for the population as a whole, including users and nonusers, and the application must address switching, quitting, starting, and use of more than one product. Neither the statute nor the rule names a required switching study. 

What has shifted is the balance the FDA strikes for ENDS, and the role hardware now plays in it. Two points anchor that balance. 

• ENDS carry the highest youth-use profile of any nicotine category, and disposables have historically been the device type most associated with youth use. That raises the risk side, and with it, the adult benefit that an applicant has to prove. 
• FDA’s comparative-efficacy approach is settled law. In FDA v. Wages and White Lion Investments, the Supreme Court upheld the FDA’s asking whether a flavored ENDS gives adult smokers an added benefit, measured against a tobacco-flavored version of the same product, that outweighs youth risk. The age-gating pathway does not overturn that test. It gives applicants a second way to satisfy it, by shrinking the youth risk the benefit has to outweigh. 

Two acronyms appear throughout the rest of this piece: HPHCs are harmful and potentially harmful constituents, the toxic chemicals measured in tobacco products, and PK is pharmacokinetics, meaning how the body absorbs nicotine from the product.

On May 5, 2026, the FDA issued marketing authorizations for four Glas closed-pod ENDS products: Classic Menthol, Fresh Menthol, Gold (mango), and Sapphire (blueberry). Gold and Sapphire are the first non-tobacco, non-menthol ENDS flavors the FDA has ever authorized. The decision rests on the Glas G2 device, which carries onboard age-gating built by a third-party technology vendor. The application was supported by an outside regulatory consulting firm. 

How the device works 

According to the FDA, the G2 device requires users to use a government-issued ID to verify their age and identity, and to pair the device with a smartphone over Bluetooth. Once verified, the device will not operate if it is separated from the phone. The app also performs periodic biometric checks to confirm that the registered adult is the one using it. The applicant showed that most adults 21 and older could easily complete verification, while youth and young adults could not. 

What the FDA actually relied on 

FDA appears to have based the authorizations mainly on the effectiveness of the age-gating and related youth-risk controls, rather than on a traditional showing that the flavored products outperformed tobacco-flavored versions in adult switching. The FDA’s acting CTP director described device access restrictions as a potential breakthrough for preventing youth use. The agency framed the result as an additional way to meet the public health standard for a non-tobacco flavor: where effective age-gating materially reduces youth risk, the amount of added adult benefit the product must show goes down. 

But the adult-benefit evidence was still there 

This is the part applicants should not miss. Glas’s application included a three-month randomized controlled switching study of about 400 adults who smoked 10 or more cigarettes a day and had no intent to quit, across four study arms, which was presented at the 2025 Tobacco Science Research Conference. During review, FDA issued an unusual second deficiency letter asking for a larger, longer switching study comparing the Glas products against authorized competitors. Glas ran it and reported that its flavored products performed even better than authorized competitors at helping adults quit. Internal FDA memos later showed that the decision was contested within the agency and elevated above the scientific staff. 

So the takeaway is not that age-gating removes the need for switching data. The Glas authorization changed how the strategy conversation goes, but it should not be read to mean that switching evidence no longer matters. Age-gating changes what the switching data has to prove. 

The key split: age-gated vs non-age-gated devices

With Glas on the books, the single most important strategic question for an ENDS applicant is whether the device carries effective onboard age-gating. The table below sets out the switching-study posture by device type and flavor. 

What "effective" age-gating means after Glas 

FDA did not credit age-gating in the abstract. It credited a specific, demonstrated set of capabilities, and applicants should expect to match it: 

• Identity and age verification tied to a government-issued ID, not a self-reported birthdate. 
• A hardware and software lock, so the device does not operate unless it is paired to the verified user's phone, and stops working when separated from it. 
• Ongoing re-authentication, such as random biometric check-ins, so the gate is not a one-time event. 
• Human-factors data showing adults can actually use it while youth and young adults cannot. 
• Anti-circumvention and anti-counterfeiting features, plus postmarket tracking and reporting on real-world youth-prevention effectiveness. 

A simple age check at the point of sale, or a basic app birthdate prompt, will not carry this. The Glas standard is a connected-device security system, closer to a regulated medical device than a typical disposable. 

Why this matters most for disposables 

There is a structural tension worth naming. The cheap, single-use disposable, which is the device type most associated with youth use, is also the hardest to fit with Glas-style age-gating, because the price and form factor do not support a Bluetooth-paired, biometric, reusable platform. In practice, the age-gating pathway favors reusable closed-pod systems. A novel-flavored disposable without age-gating sits in the worst position of all: highest youth risk, no hardware mitigation, and no precedent for authorization. 

How to think about the study decision 

The answer now depends on both flavor and device. 

Non-age-gated device, novel or menthol flavor. A switching study is effectively required. Without hardware mitigation, the product has to win the comparative-efficacy argument, and that takes a strong, product-specific switching study. Even then, no non-age-gated sweet flavor has been authorized. 

Age-gated device, any flavor. A switching study is still expected, but its job shifts. Glas shows the study no longer has to prove the flavor beats tobacco on switching. It does have to show that a credible adult-quitting benefit exists. FDA demanded substantial longitudinal switching data from Glas even with best-in-class age-gating, so do not plan to skip it. 

Any device, tobacco flavor. A switching study is advisable but not strictly required. This tier is the closest ENDS analog to the nicotine pouch situation, where the full evidence package can carry the case. 

Put another way, for a non-age-gated device the switching study is the deciding evidence for any non-tobacco flavor. For an age-gated device it is still expected, but its purpose moves from winning a comparison to showing that a genuine adult benefit sits alongside the youth-risk controls.

What this means for applicants

• Decide the device architecture first. It sets the entire evidence strategy. If you intend to market novel flavors, seriously evaluate building Glas-style onboard age-gating into a reusable closed-pod platform. It is now the only proven route to a non-tobacco, non-menthol authorization. 
• For a non-age-gated device with any non-tobacco flavor, plan on a strong comparative switching study from the start. Show, with reliable product-specific data, higher complete-switching or significant-reduction rates than a tobacco-flavored version of the same product. Without it, expect denial. 
• For an age-gated device, still budget for a robust switching study. Aim it at proving a real adult benefit rather than beating tobacco flavor. Follow the Glas model: a multi-arm randomized switching study in adult smokers, and be ready for the FDA to ask for longer follow-on data even with strong age-gating. 
• Invest in the age-gating evidence to the Glas standard, not a token gate. That means ID-based verification, a device-to-phone proximity lock, ongoing biometric re-authentication, human-factors data showing adults can and youth cannot use it, and postmarket effectiveness tracking. A weak gate gets no credit. 
• Treat novel-flavored disposables without age-gating as the highest-risk filing. Highest youth risk, no hardware mitigation, no supporting precedent. Counsel clients candidly before they spend on these. 
• Frame the position with care. Do not tell the FDA that a switching study is not needed, even with age-gating. Say it is not categorically required, but that its value is decisive in the tiers where it matters, and that you have weighed that value against the remaining uncertainty for this specific flavor, device, and youth-mitigation design. 

How Accorto can help

We start with your device architecture and flavor lineup, settle the switching-study question for each product, then build the strongest defensible submission for the products worth filing. A typical engagement runs in four phases. 

Phase 1: Device and portfolio triage (about 2 to 4 weeks) 

• Confirm whether your device can support effective onboard age-gating to the Glas standard, or whether a reusable age-gated platform is worth developing for your flavored products. 
• Sort every product by flavor tier and by device type, such as age-gated pod, non-age-gated pod, or disposable. 
• Deliver a go or no-go and a switching-study recommendation for each product, so you do not spend on filings that cannot clear the bar. 

Phase 2: Age-gating evidence and switching study design 

• Age-gating package: specify and document ID verification, the device-to-phone proximity lock, biometric re-authentication, anti-counterfeiting, human-factors testing, and postmarket effectiveness tracking, modeled on the Glas approach. 
• Switching study: for non-age-gated non-tobacco flavors, a comparative study against a tobacco-flavored version; for age-gated flavors, a multi-arm randomized study proving a real adult benefit, designed to withstand a possible FDA request for longer follow-on data. 

Phase 3: Youth-risk module and population-health analysis 

• Build the labeling, marketing limits, and access-control package, and tie the age-gating record directly to the youth-risk side of the balance. 
• Run population-health modeling that, like Glas, can attribute added benefit to age-gating relative to ENDS that lack such controls. 

Phase 4: Application assembly and filing 

• Assemble the full Part 1114 application, including device and product bridging, scientific summaries, and the integrated APPH argument. 
• Run a pre-submission quality and deficiency-risk review, anticipating the kind of second-deficiency request Glas faced, then support you through FDA review and any state-directory questions on the disposable side. 

If it would help, a Phase 1 device and portfolio triage gives you a per-product, precedent-based recommendation on which ENDS products to file, whether your device needs onboard age-gating, and which products need a switching study and of what design, usually within about four weeks. 

Dr. Vincent Angelico

Chief Science Officer & Co-Founder

Dr. Vincent Angelico is the Chief Science Officer and a co-founder of Accorto Regulatory Solutions. He holds a PhD in Analytical Chemistry and specializes in FDA regulatory strategy for tobacco harm reduction products, with deep experience in PMTA submissions, consumer behavior research, and population-health analysis for nicotine pouches and smoke-free alternatives. He has guided THR programs through every stage of the FDA review process, from initial product classification through substantive review and deficiency response.

This is general regulatory and scientific analysis from Accorto Regulatory Solution. It reflects FDA decisions and public information available as of June 2026 and is not legal advice. Regulatory expectations change, so please confirm current FDA guidance and authorized-product details before acting on anything here.